MedPath

Corticosteroid in acute urticaria in emergency department

Phase 1
Recruiting
Conditions
Adults patients with isolated acute urticaria presenting to the emergency department
MedDRA version: 21.1Level: LLTClassification code: 10001106Term: Acute urticaria Class: 10040785
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Registration Number
CTIS2024-515308-38-00
Lead Sponsor
Assistance Publique Hopitaux De Paris
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
240
Inclusion Criteria

Age > 18 years, Acute urticaria with angioedema without laryngeal edema, Obtain patient’s consent, Social security affiliation

Exclusion Criteria

Pregnancy or breastfeeding, Atopic dermatitis, Eczema, Bullous pemphigoid, Acute exanthematous pustulosis, Diabetes mellitus, Gastrointestinal ulcer, Refusal to participate, Known allergy to the study drugs or formulation ingredients, Hypersensitivity to lactose, Known Renal failure defined by creatinine clearance < 10 mL/min or cardiac failure defined by ejection fraction < 40%, Acute hives with anaphylaxis, Hypersensitivity to active substance, to cetirizine, to hydroxyzine and to pipérazine and excipients, Contre-indication to corticotherapy: o Any live vaccine o Psychotic states still uncontrolled by treatment limiting the participant's compliance with the research o Some viruses in evolution (including hepatitis, herpes, chicken pox, shingles). o Any infectious condition, Bradykinin angioedema, Angioedema without urticaria (hives), Laryngeal edema with urticaria (hives), Corticosteroid administration in the previous 5 days visiting the emergency department, Antihistamines greater than 1 tablet per day in the previous 5 days visiting the ED, Other treatment for urticaria : omalizumab, montelukast, ciclosporine A, Chronic urticaria before acute urticaria diagnosis

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath